Testosterone pellets: what TikTok gets right and wrong

What did @trt__np actually say?

The creator, presenting as a nurse practitioner, came out swinging against testosterone pellets in response to a patient who had just booked an insertion appointment. The core argument: pellets give you zero dosing control, they "spike your red blood cells," they "plummet your SHBG," they fall out in the shower about half the time, and patients can be stuck riding out unpredictable hormone levels for six to nine months. The NP also claimed they have "never seen good results on testosterone pellets for men, ever" and that pellets force patients to wait out a hormonal crash before switching to injections. They finished with a pitch for their own practice.

To be fair, this is clinical opinion grounded in real patient experience, not fringe internet advice. Some of the concerns raised here have genuine support in the literature. But several specific claims are overstated, one statistic appears fabricated, and the absolutism throughout does a disservice to patients trying to make informed decisions.

Does the science back this up?

Partly. The concern about elevated hematocrit with pellets is well-documented. A study by Pastuszak et al. (2015, Journal of Sexual Medicine) found that pellet-dosed men showed significantly higher rates of polycythemia compared to men on topical testosterone. Elevated red blood cell production is a real, monitored risk across all testosterone delivery methods, but pellets do appear to produce more pronounced erythrocytosis in some patients.

The SHBG suppression claim also has a basis in reality. Because pellets deliver a continuous, relatively high-dose testosterone load, SHBG suppression can be more pronounced than with weekly or twice-weekly injections. Lower SHBG means more free testosterone, which is not inherently bad, but it does complicate interpretation of standard lab panels.

On extrusion, a systematic review by Fears et al. (2023, Sexual Medicine Reviews) documented extrusion rates ranging from roughly 1% to 9% depending on pellet type, insertion site, and activity level. The NP's claim that "50% of the time guys... will bore out of their body" is not supported by published data. That number is off by a significant margin and should not be repeated as fact.

What did they get wrong (or right)?

The extrusion rate claim is the clearest factual error here. A 50% extrusion rate is not what the literature shows. The actual published range sits well under 10% in most studies. Repeating that figure to a patient who just booked an appointment is the kind of thing that erodes trust in clinical content broadly.

The "no control" argument is more nuanced than presented. Pellet dosing protocols have become more refined. Clinicians can adjust pellet count and pellet size at insertion based on weight, baseline testosterone, and symptom burden. That is not the same as the day-to-day titration you get with injections, but calling it zero control misrepresents how experienced pellet providers actually work.

Where the NP deserves credit: the point about getting "stuck" is legitimate. Unlike injections or gels, you cannot simply stop a pellet. If a patient develops polycythemia, a hematocrit above 54%, or feels miserable on too-high levels, there is no easy off switch. That is a real clinical limitation, and it is a reasonable basis for preference toward injectable or topical delivery in patients who may need frequent dose adjustments.

What should you actually know?

No testosterone delivery method is universally best. Pellets, injections, gels, and patches each carry distinct pharmacokinetic profiles, side effect risks, and lifestyle trade-offs. A 2021 review by Ramasamy et al. in Therapeutic Advances in Urology compared delivery methods and found that patient satisfaction data does not cleanly favor one approach. Some men do well on pellets. Some do not.

The "crash" concern when transitioning off pellets is real and underappreciated. As pellets deplete, testosterone can drop below baseline before clearing completely. A provider who understands this transition and manages it proactively adds genuine value. The NP's claim to have developed a protocol for this is not implausible, though no peer-reviewed data supports the specific approach described.

If you are considering any form of TRT, the delivery method conversation matters far less than baseline labs, monitoring frequency, and whether your provider will actually respond when something goes wrong. That part of the NP's message, "you call me, I fix it right then and there," reflects a real advantage of titratable delivery systems, even if the surrounding claims were not all accurate.